Aakaar Medical Technologies Limited · NSE:AAKAAR
Aakaar Medical Technologies — H1FY2025-26 Earnings Presentation
44 slides from Aakaar Medical Technologies's earnings presentation, Nov 10, 2025
Slide 1: Cover letter to NSE: Outcome of Board Meeting
Aakaar Medical Technologies Limited (formerly: Aakaar Medical Technologies Pvt.Ltd.) A-801, Heritage Plaza, Teli Gali Cross Road Andheri (East), Mumbai – 400 069 INDIA Mob: + 91 9820317468 E-mail: info@aakaarmedical.in CIN No.: L74900MH2013PLC244717 www.aakaarmedical.in GST No: 27AALCA7587Q1ZK Novem
Slide 2: H1FY2025-26 Results Press Release
Aakaar Medical Technologies Ltd. announces H1FY2025-26 Results Stable operations amidst strategic realignment; H2 to comeback stronger Mumbai, Nov 10, 2025: Aakaar Medical Technologies Ltd. (NSE: AAKAAR) today announced the unaudited financial results for the quarter ended September 30, 2025. INR Cr
Slide 3: About Aakaar Medical Technologies Limited
ABOUT AAKAAR MEDICAL TECHNOLOGIES LIMITED [formerly Aakaar Medical Technologies Pvt.Ltd.] Company contact Investor Relations Team Mr. Anoopkumar Pillai, Soumya Chhajed Company Secretary & Compliance Officer Email- soumya@goindiaadvisors.com A-801, Heritage Plaza, Teli Gali Cross Road Mobile: +91-861
Slide 4: Aakaar Medical Technologies Limited
Aakaar Medical Technologies Limited Investor Presentation 10.11.2025
Slide 5: Disclaimer
Disclaimer This presentation contains certain “forward looking statements” that are based on current expectations, assumptions, estimates and projections about the business, financial performance, industry trends and markets in which we operate. Such statements include, but are not limited to, those
Slide 6: Reinventing Beauty – Tech in India
Aakaar Medical Technologies Reinventing Beauty – Tech in India 01 02 03 About the Company H1FY26 Highlights Annexure Investor Presentation - 2025 3
Slide 7: Company at a Glance
Company at a Glance (Details For the Period FY24-25) INR 62 Cr. 21% & 26% INR 6 Cr 5,236 Revenue up 34% Cash and Cash Customers ROCE & ROE YoY Equivalents INR 10 Cr. INR 6 Cr INR 27 Cr 154 IPO proceeds to fund SKUs EBITDA up 94% PAT up 107% YoY working capital YoY with +535 bps with +360 bps require
Slide 8: Comprehensive Business Segments of Aesthetics Products, Devices & Device Consumables
Comprehensive Business Segments of Aesthetics Products, Devices & Device Consumables Key Business Segments A. Aesthetics Products B. Aesthetics Devices & Device Consumables Clinical and aesthetics devices & device Products for hair care, skin care & injectables which consumables, catering to diverse
Slide 9: The gap in India's Aesthetic Care Market
The gap in India’s Aesthetic Care Market India’s aesthetics market is expanding at a ~14% CAGR How underpenetrated is the India's market: till 2030, yet 80% of products remain imported — 1 dermat designated for ~75k people exposing weak local capabilities 5,00,000 27000 30000 4,50,000 4,50,000 25000
Slide 10: Solution: Aakaar's High growth, Margin accretive and Asset light
Solution: Aakaar’s High growth, Margin accretive and Asset light Revenue Engine – Product-led; Recurring growth o Aesthetic Products occupying 83% giving a recurring business Number of SMEs in Medical Aesthetics and o Transition to Owned brands build margins and defensibility 30-34 Cosmetic Dermatol
Slide 11: Resilience amidst all the odds – PAT positive since last 10 years
Resilience amidst all the odds – PAT positive since last 10 years All values in INR Cr. 6.0 2.2 2.4 1.7 1.8 1.8 2.0 0.8 0.5 FY17 FY18 FY19 FY20 FY21 FY22 FY23 FY24 FY25 Industry India Banking stress IL&FS COVID-19 COVID 2nd Ukraine Recovery Wide demonetization Startup default Outbreak wave war Headw
Slide 12: Strong Segment Growth across Entire Spectrum of Aesthetics Solutions
Strong Segment Growth across Entire Spectrum of Aesthetics Solutions All values in INR Cr. Revenue growth over last 2 years Injectable & Aesthetics Devices & Professional Homecare for Skin Professional Contouring Device Consumables Skincare & Hair Haircare 17 12 7 8 17 6 8 9 5 1 FY23 FY25 FY23 FY25
Slide 13: Strong Brand Portfolio – Top 10 Products
Strong Brand Portfolio – Top 10 Products FY25 Revenue FY 23-25 Product Product Segment (INR Cr)* CAGR Top 10 own products contribution as % share of revenue from operations Inno Exfo Lightening 15gm Professional Skin Care 8.8 19% FY23 17% Siax Injectables & Contouring 5.0 34% FY24 20% TUBELiTE GFC 3
Slide 14: Transitioning to Margin Accretive Model
Transitioning to Margin Accretive Model All values in INR Cr. 71% 72% 74% 86% 25% 24% 22% 27% 24% 30% 38% 21% 20% 21% 17% 21% 47% 46% 45% 43% 53 14 24 34 23 5 8 14 FY22 FY23 FY24 FY25 FY22 FY23 FY24 FY25 FY22 FY23 FY24 FY25 Owned brands as a % of revenue Products as % of revenue COGS as a % of sales
Slide 15: Divisionalization: Driving Depth, Reach & Revenue
Divisionalization: Driving Depth, Reach & Revenue All values in INR Cr. Sales growth after divisionalization >3x Higher MR growth subdues MR productivity (still above industry average) but sales growth to pick at a faster rate 61 37 67 98 129 46 33 19 8 7 6 5 FY22 FY23 FY24 FY25 FY22 FY23 FY24 FY25
Slide 16: About our new division - EXOVEA
About our new division - EXOVEA Introducing India’s first premium range of synthetic exosomes powered by PDRN and plant stem cells, blending Italian innovation with Indian expertise. EXOVEA debuts with 8 clinically proven, premium formulations, setting new benchmarks in regenerative skincare and aes
Slide 17: Growth Levers
Growth Levers All values in INR Cr. Launching high growth brands As sales team strengthens, Doctor Increasing number of doctors per brand outreach has been soaring high (SKU wise split) 163 9,000 147 129 4403 140 4131 8,000 121 121 3443 7,000 98 6,000 2257 5,000 67 4,000 37 3,000 FY22 FY23 FY24 FY25
Slide 18: Expanding Market Reach: Serving Medical Professionals Nationwide
Expanding Market Reach: Serving Medical Professionals Nationwide + 5,000 100 1,000 20 + + + Dermats & Clinics MR executives Pharmacies Stockists Reduced reliance on The company's strategy of using doctor-dispensed products has successfully top 10 customers expanded its reach to a larger market, bene
Slide 19: PAN India Distribution Strength Reflected in Aakaar's Geographical Reach
PAN India Distribution Strength Reflected in Aakaar’s Geographical Reach Punjab 6.1% INR 3.7 Cr Delhi 6.8% INR 4.2 Cr Aakaar’s nation-wide presence ensures reliable 5.6% Haryana Uttar Pradesh 7.9% INR 3.5 Cr INR 4.9 Cr supply, with ~84% of company’s revenue coming from 4.3% Gujarat INR 2.6 Cr its to
Slide 20: Robust Distribution Network
Robust Distribution Network Aakaar Medical (Andheri) Strategic Nationwide Distribution Backbone Distribution Model 1 Distribution Model 2 Distribution Model 3 ❑Pan-India Reach, Zero Capex: National warehousing network through PISPL delivers scale without capital Dermatologists, Dentists, PISPL Centr
Slide 21: Industry Dynamics Driving Working Capital, but Normalizing Ahead
Industry Dynamics Driving Working Capital, but Normalizing Ahead All values in INR Cr. 222 222 222 40% 22.7 21.9 200 36% 28% 26% 15.1 131 12.2 105 105 88 9.3 7.9 5.9 50 38 38 37 3.8 FY22 FY23 FY24 FY25 FY22 FY23 FY24 FY25 FY22 FY23 FY24 FY25 Receivables Days Payables Days Inventory Days Total workin
Slide 22: The balance sheet Reset - Utilizing IPO Proceeds for growth ahead
The balance sheet Reset - Utilizing INR 27 Cr for growth ahead.. All values in INR Cr. 131 7 11 9 IPO Breakup (INR 27 Cr.) 60 21.6 20 Proceeds normalizing WC requirements Recievable days Funding WC requirements Corporate Purposes FY25 FY28E Current WC IPO Chunk FY26E IPO Chunk FY27E An estimated INR
Slide 23: H1FY26 Highlights
enhancing life through technology 02 HiFY26 Highlights
Slide 24: Stable operations amid strategic realignment; Poised for strong H2 ahead
Stable operations amid strategic realignment; Poised for strong H2 ahead… Seasonal & Strategic Transition Impact Revenue at ₹25.3 Cr (-8.6% YoY) reflects normal H1 seasonality , historically softer than H2 - and deliberate tightening of credit terms to enhance long-term cash flow stability. Inventor
Slide 25: Half year performance
Half year performance All values in INR Cr. Key Financial Performance H1FY25 H1FY26 Y-O-Y Revenue from operations 27.7 25.3 (8.7)% EBITDA 1.5 0.07 (95.3)% EBITDA Margin 5.4% 0.3% (510) Bps PAT 0.5 (0.8) (260.0)% (470) bps PAT Margin 1.7% (3.1)% Adjusted Net Worth 14.3 47.1 - Return on Net Worth 3.3%
Slide 26: Key Performance Indicators
Key Performance Indicators All values in INR Cr. Key Financial Performance FY23 FY24 FY25 H1FY26 Revenue from operations 32.8 46.1 61.6 25.3 EBITDA 4.0 4.9 9.9 0.07 EBITDA Margin 12.3% 10.7% 16.2% 0.3% PAT 2.5 2.0 6.0 (0.8) PAT Margin 7.5% 4.4% 9.8% (3.0)% Adjusted Net Worth 10.6 12.6 23.3 47.1 Retu
Slide 27: Statement of Profit and Loss
Statement of Profit and Loss All values in INR Cr. Particulars FY23 FY24 FY25 H1FY26 Revenue from operations 32.8 46.1 61.6 25.3 Other income 0.1 0.2 0.2 0.3 Total Income 32.9 46.3 61.8 25.6 COGS 15.0 20.9 26.2 11.4 Gross Profit 17.8 25.2 35.4 13.9 Margin 54.2% 54.6% 57.4% 54.8% Employee benefits ex
Slide 28: Balance Sheet Items
Balance Sheet Items All values in INR Cr. Particulars FY23 FY24 FY25 H1FY26 Particulars FY 23 FY 24 FY25 H1FY26 Equity and Liabilities Non-Current Assets Property, Plant & Equipment Shareholders’ funds 0.4 0.3 0.2 0.2 (PPE) a. Share capital 0.7 0.7 10.4 14.2 Intangible assets 0.01 0.01 0.01 0.02 b.
Slide 29: Annexure
enhancing life through technology 03 Annexure
Slide 30: Consistent Product Launch
Consistent Product Launch Maxwave Devices Fotofinder DRS1512 Skin/Hair Extreluxe Nucleotide Consumables Etrelume Lyftox Medifacial Tinefcon Launch Year 2010 2011 2013 2014 2015 2017 2018 2019 2020 2021 2022 2023 2024 2025 In-House Product Imported Products Investor Presentation - 2025 27
Slide 31: Focused on strengthening MR skills
Focused on strengthening MR skills The Program is Designed to Train and Certify Practicing Dermatologists & Students on theory & practical knowledge of: + 5,000 MICA 129 1,134 Dermal Fillers Threads 23 Toxins (Masterclasss in Contouring Aesthetics) Dermats & Clinics Pharmacies Conducted under tutela
Slide 32: Creating market through consistent trainings & workshops
Creating market through consistent trainings & workshops + 5,000 129 1,134 23 • Conducted >950 workshops to train Dermatologist & Dermats & Clinics Pharmacies Cosmetic practitioners • MICA, hands-on workshop is conducted across Tier-I & II cities to provide training to the practitioners • Participat
Slide 33: Experienced and Passionate Leadership Team
Experienced and Passionate Leadership Team Founder & MD CEO & Executive Director Chief Financial Officer Company Secretary Mr. Dilip Meswani Dr. Rahul Sawakhande Ms. Sweta Shah Mr. Anoopkumar Pillai o He is the Managing Director and o He is the CEO and Executive Director o She is the CFO of our comp
Slide 34: Supported by Strong Directors and Management Team
Supported by Strong Directors and Management Team Independent Director Independent Director National Sales Head National Sales Head Mr. Rajendra Dhandhukia Mr. Deepanjan Periwal Mr. Saurabh Chamoli Mr. Deepak Sharma o He is the Independent Director of our o He is the Independent Director of our o He
Slide 35: Aakaar is Uniquely Positioned in a Competitive Market
Aakaar is Uniquely Positioned in a Competitive Market Types of Offerings Types of Products and/or Devices Offered Facial Body Contouring Tattoo Products Devices Hair Removal Aesthetics & Injectables Removal Investor Presentation - 2025 32
Slide 36: Aakaar's Complete Range of Aesthetics Products
A. Aesthetics Products B. Aesthetics Devices & Device Consumables A. Aakaar’s Complete Range of Aesthetics Products Professional Skin Care Range Addresses diverse skin concerns, combining science and innovation to deliver outstanding results. Includes peels, medi-facials, etc Professional Hair Care
Slide 37: Aakaar Brand: Extensive Range of Aesthetics Product SKUs
Aakaar Brand: Extensive Range of 47 Aesthetics Product SKUs FY 2024 FY 2025 Company’s 11 years of experience ensures their home- grown aesthetic products deliver premium quality and INR 8.9 Cr INR 19.8 Cr superior results Revenue from own brand products Revenue from own brand products Professional S
Slide 38: Imported/Third Party Brands: Rights to Distribute Aesthetics Product SKUs
Imported/Third Party Brands: Rights to Distribute 63 Aesthetics Product SKUs FY 2024 FY 2025 Providing Indian consumers with exclusive access to renowned global skincare and aesthetics brands INR 25.3 Cr INR 33.2 Cr Revenue from own brand products Revenue from own brand products Introducing innovati
Slide 39: Strengthening Products Portfolio through In-licensing Tie-ups with International Brands
Strengthening Products Portfolio through In-licensing Tie-ups with Reputable International Brands Aakaar’s in-licensing agreements and collaborations with renowned international aesthetic brands allow them to distribute select high-demand products across India, currently contributing to 70% of their
Slide 40: Aesthetics Devices & Device Consumables
B. Aesthetics Devices & Device Consumables Range of Devices and Device Consumables for Innovative Aesthetics Solutions Aakaar’s aesthetic devices utilize cutting-edge technology tailored to diverse skincare and haircare needs, with each device Brands Offered engineered for precision, safety and effi
Slide 41: From Concept to Commercial Release: Product Development Journey
From Concept to Commercial Release: Aakaar’s Product Development Journey Research & Ideation – Concept Development Feasibility Prototype Development 1 Month – 1 Month Analysis – 1 Month – 2 Months ✓ Market research ✓ Select promising ideas ✓ Assess technical feasibility ✓ Create prototypes for testi
Slide 42: Ideation to Launch for Imported Products
Ideation to Launch for Imported Products Research & Ideation – Identification – 1 Feasibility Prototype Development 1 Month Month Analysis – 1 Month – 1 Month ✓ Market research ✓ Evaluate Idea ✓ Assess technical feasibility ✓ Import product Samples ✓ Identify trends and consumer needs ✓ Conduct Conc
Slide 43: Key Clients
Key Clients Aakaar’s clients encompass a wide range of professionals and corporates, from individual doctors to renowned dermatology clinics, ensuring personalized and high-quality care Some of Aakaar’s esteemed clients include: 01 One of the largest chains of slimming, beauty, and 05 Clinic with 27
Slide 44: Thank You
Thank You For further information, please get in touch with: Company Contact Anoopkumar Pillai Company Secretary +91 84528 44024 Investor Relations Contact Contact Name soumya@GoIndiaadvisors.com +91 8619707750 41
Aakaar Medical Technologies — H1FY2025-26 Earnings Presentation on 6ix